2-氨基-4-异丙氧基-5-甲氧基苯甲酸甲酯 | 50413-53-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-4-异丙氧基-5-甲氧基苯甲酸甲酯
• 中文别名: 4-异丙氧基-5-甲氧基-2-氨基苯甲酸甲酯
• 英文名称: methyl 2-amino-4-isopropoxy-5-methoxybenzoate
• 英文别名: methyl 2-amino-5-methoxy-4-propan-2-yloxybenzoate
• CAS: 50413-53-1
• 化学式: C₁₂H₁₇NO₄
• 分子量: 239.271
• InChiKey: BSYREQYBSSODKV-UHFFFAOYSA-N

物化性质

• 沸点：
  363℃
• 密度：
  1.133
• 闪点：
  156℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  2-氨基-4-异丙氧基-5-甲氧基苯甲酸甲酯 在 三氯化铝 、 三氯氧磷 作用下， 生成 4-氯-7-羟基-6-甲氧基喹啉-3-甲腈
  参考文献：
  名称：

  Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines

  摘要：

  Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00493-5
• 作为产物：
  描述：

  4-异丙氧基-3-甲氧基苯甲酸甲酯 在 硝酸 、 铁粉 、 氯化铵 作用下， 生成 2-氨基-4-异丙氧基-5-甲氧基苯甲酸甲酯
  参考文献：
  名称：

  Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines

  摘要：

  Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00493-5

文献信息

• PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1719771A1

  公开（公告）日：2006-11-08

  The present invention provides a pyarzoloquinolone derivative having kinase inhibitory activity. The derivative is represented by the formula: wherein R1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be substituted; R2 is a hydrogen atom, an amino group which may be substituted, a hydroxy group which may be substituted, or a thiol group which may be substituted; R3, R4, R5 and R6, which may be identical or different, are each (1) a hydrogen atom, (2) a nitro group, (3) a cyano group, (4) a halogen atom, (5) a hydrocarbon group which may be substituted, (6) an amino group which may be substituted, (7) a hydroxy group which may be substituted, or (8) a thiol group which may be substituted; and R3 and R4, R4 and R5, and R5 and R6 may respectively form a ring together with the adjacent carbon atom, or salt thereof.

  本发明提供了一种具有激酶抑制活性的吡唑喹啉衍生物。该衍生物由以下式表示： 其中R1是可以被取代的芳基或可以被取代的芳香杂环基；R2是氢原子、可以被取代的氨基、可以被取代的羟基或可以被取代的硫基；R3、R4、R5和R6，可以相同也可以不同，分别是（1）氢原子、（2）硝基、（3）氰基、（4）卤原子、（5）可以被取代的碳氢基、（6）可以被取代的氨基、（7）可以被取代的羟基或（8）可以被取代的硫基；且R3和R4、R4和R5、以及R5和R6可以分别与相邻的碳原子形成环，或其盐。
• Pyrazoloquinolone Derivative And Use Thereof
  申请人：Fukumoto Shojl

  公开号：US20070281963A1

  公开（公告）日：2007-12-06

  The present invention provides a pyarzoloquinolone derivative having kinase inhibitory activity. The derivative is represented by the formula: wherein R 1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be substituted; R 2 is a hydrogen atom, an amino group which may be substituted, a hydroxy group which may be substituted, or a thiol group which may be substituted; R 3 , R 4 , R 5 and R 6 , which may be identical or different, are each (1) a hydrogen atom, (2) a nitro group, (3) a cyano group, (4) a halogen atom, (5) a hydrocarbon group which may be substituted, (6) an amino group which may be substituted, (7) a hydroxy group which may be substituted, or (8) a thiol group which may be substituted; and R 3 and R 4 , R 4 and R 5 , and R 5 and R 6 may respectively form a ring together with the adjacent carbon atom, or salt thereof.

  本发明提供了一种具有激酶抑制活性的吡唑喹啉衍生物。该衍生物由以下公式表示：其中，R1是可以被取代的芳基或可以被取代的芳香杂环基；R2是氢原子，可以被取代的氨基，可以被取代的羟基或可以被取代的硫醇基；R3、R4、R5和R6可以相同也可以不同，分别是（1）氢原子，（2）硝基，（3）氰基，（4）卤原子，（5）可以被取代的碳氢基，（6）可以被取代的氨基，（7）可以被取代的羟基或（8）可以被取代的硫醇基；R3和R4，R4和R5，以及R5和R6可以分别与相邻的碳原子形成环，或其盐。
• Pyrazoloquinolone derivative and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07842701B2

  公开（公告）日：2010-11-30

  The present invention provides a pyarzoloquinolone derivative having kinase inhibitory activity. The derivative is represented by the formula: wherein R1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be substituted; R2 is a hydrogen atom, an amino group which may be substituted, a hydroxy group which may be substituted, or a thiol group which may be substituted; R3, R4, R5 and R6, which may be identical or different, are each (1) a hydrogen atom, (2) a nitro group, (3) a cyano group, (4) a halogen atom, (5) a hydrocarbon group which may be substituted, (6) an amino group which may be substituted, (7) a hydroxy group which may be substituted, or (8) a thiol group which may be substituted; and R3 and R4, R4 and R5, and R5 and R6 may respectively form a ring together with the adjacent carbon atom, or salt thereof.

  本发明提供了一种具有激酶抑制活性的吡唑醌衍生物。该衍生物由以下公式表示：其中，R1是可以被取代的芳基或可以被取代的芳香杂环基；R2是氢原子、可以被取代的氨基、可以被取代的羟基或可以被取代的硫醇基；R3、R4、R5和R6是可以相同或不同的(1)氢原子、(2)硝基、(3)氰基、(4)卤素原子、(5)可以被取代的碳氢基、(6)可以被取代的氨基、(7)可以被取代的羟基或(8)可以被取代的硫醇基；而且R3和R4、R4和R5以及R5和R6可以与相邻的碳原子一起形成环，或其盐。
• US7842701B2
  申请人：——

  公开号：US7842701B2

  公开（公告）日：2010-11-30
• Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines
  作者：Yanong D. Wang、Karen Miller、Diane H. Boschelli、Fei Ye、Biqi Wu、M.Brawner Floyd、Dennis W. Powell、Allan Wissner、Jennifer M. Weber、Frank Boschelli

  DOI：10.1016/s0960-894x(00)00493-5

  日期：2000.11

  Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.